## **Audit Review Table**

Parkland Community Health Plan (Org ID: 19735, SubID: 11066, Medicaid, Spec Area: None, Spec Proj: SCHIP, Contract Number: None)

Measurement Year - 2017; Date & Timestamp - 6/27/2018 2:55:12 PM

The Auditor lock has been applied to this submission.

Measure/Data Element	Benefit Offered	Rate	Audit Designation	Comment		
Effectiveness of Care: Prevention and						
Adult BMI Assessment (aba)			NQ	Not Required		
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)						
BMI Percentile		72.26%	R	Reportable		
Counseling for Nutrition		74.94%	R	Reportable		
Counseling for Physical Activity		67.88%	R	Reportable		
Childhood Immunization Status (cis)						
DTaP		89.78%	R	Reportable		
IPV		94.40%	R	Reportable		
MMR		97.08%	R	Reportable		
HiB		95.38%	R	Reportable		
Hepatitis B		91.00%	R	Reportable		
VZV		96.84%	R	Reportable		
Pneumococcal Conjugate		91.73%	R	Reportable		
Hepatitis A		96.35%	R	Reportable		
Rotavirus		85.40%	R	Reportable		
Influenza		54.74%	R	Reportable		
Combination #2		83.21%	R	Reportable		
Combination #3		82.24%	R	Reportable		
Combination #4		81.27%	R	Reportable		
Combination #5		75.18%	R	Reportable		
Combination #6		48.18%	R	Reportable		
Combination #7		74.45%	R	Reportable		
Combination #8		47.69%	R	Reportable		
Combination #9		45.50%	R	Reportable		
Combination #10		45.01%	R	Reportable		
Immunizations for Adolescents (ima)						
Meningococcal		92.46%	R	Reportable		

Tdap		93.43%	R	Reportable
HPV		39.42%	R	Reportable
Combination #1		91.73%	R	Reportable
Combination #2		38.44%	R	Reportable
Lead Screening in Children (Isc)		72.51%	R	Reportable
Breast Cancer Screening (bcs)			NQ	Not Required
Cervical Cancer Screening (ccs)			NQ	Not Required
Chlamydia Screening in Women (chl)				
16-20 Years			NQ	Not Required
21-24 Years			NQ	Not Required
Total			NQ	Not Required
Effectiveness of Care: Respiratory				
Appropriate Testing for Children with Pharyngitis (cwp)	Υ	87.24%	R	Reportable
Use of Spirometry Testing in the Assessment and				
Diagnosis			NQ	Not Required
of COPD (spr)				
Pharmacotherapy Management of COPD Exacerbation	Υ			
(pce)	•			
Systemic Corticosteroid			NQ	Not Required
Bronchodilator			NQ	Not Required
Medication Management for People With Asthma (mma)	Υ			
5-11 Years: Medication Compliance 50%		44.44%	R	Reportable
5-11 Years: Medication Compliance 75%		18.52%	R	Reportable
12-18 Years: Medication Compliance 50%		37.62%	R	Reportable
12-18 Years: Medication Compliance 75%		19.80%	R	Reportable
19-50 Years: Medication Compliance 50%			NA	Small Denominator
19-50 Years: Medication Compliance 75%			NA	Small Denominator
51-64 Years: Medication Compliance 50%			NA	Small Denominator
51-64 Years: Medication Compliance 75%			NA	Small Denominator
Total: Medication Compliance 50%		42.07%	R	Reportable
Total: Medication Compliance 75%		18.97%	R	Reportable
Asthma Medication Ratio (amr)	Y			
5-11 Years		76.02%	R	Reportable
12-18 Years		70.48%	R	Reportable

19-50 Years			NA	Small Denominator
51-64 Years			NA	Small Denominator
Total		74.09%	R	Reportable
Effectiveness of Care: Cardiovascular				
Controlling High Blood Pressure (cbp)			NQ	Not Required
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Υ		NQ	Not Required
Statin Therapy for Patients With Cardiovascular	.,			
Disease (spc)	Υ			
Received Statin Therapy: 21-75 Years (Male)			NQ	Not Required
Statin Adherence 80%: 21-75 Years (Male)			NQ	Not Required
Received Statin Therapy: 40-75 Years (Female)			NQ	Not Required
Statin Adherence 80%: 40-75 Years (Female)			NQ	Not Required
Received Statin Therapy: Total			NQ	Not Required
Statin Adherence 80%: Total			NQ	Not Required
Effectiveness of Care: Diabetes				
Comprehensive Diabetes Care (cdc)				
Hemoglobin A1c (HbA1c) Testing			NQ	Not Required
HbA1c Poor Control (>9.0%)			NQ	Not Required
HbA1c Control (<8.0%)			NQ	Not Required
HbA1c Control (<7.0%)			NQ	Not Required
Eye Exam (Retinal) Performed			NQ	Not Required
Medical Attention for Nephropathy			NQ	Not Required
Blood Pressure Control (<140/90 mm Hg)			NQ	Not Required
Statin Therapy for Patients With Diabetes (spd)	Υ			
Received Statin Therapy			NQ	Not Required
Statin Adherence 80%			NQ	Not Required
Effectiveness of Care: Musculoskeletal				
Disease-Modifying Anti-Rheumatic Drug Therapy in	Υ		NQ	Not Required
Rheumatoid Arthritis (art)	<u>'</u>		IVQ	Not Required
Effectiveness of Care: Behavioral				
Antidepressant Medication Management (amm)	Y			
Effective Acute Phase Treatment			NQ	Not Required
Effective Continuation Phase Treatment			NQ	Not Required
Follow-Up Care for Children Prescribed ADHD	Υ			
Medication (add)	<u>.</u>			

Initiation Phase		29.33%	R	Reportable
Continuation and Maintenance (C&M) Phase		23.33%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	N	20.0070	N.	reportable
30-Day Follow-Up			NB	No Benefit
7-Day Follow-Up			NB	No Benefit
Follow-Up After Emergency Department Visit for Mental Illness (fum)	N			
30-Day Follow-Up			NB	No Benefit
7-Day Follow-Up			NB	No Benefit
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (fu	N			
30-Day Follow-Up: 13-17 Years			NB	No Benefit
7-Day Follow-Up: 13-17 Years			NB	No Benefit
30-Day Follow-Up: 18+ Years			NB	No Benefit
7-Day Follow-Up: 18+ Years			NB	No Benefit
30-Day Follow-Up: Total			NB	No Benefit
7-Day Follow-Up: Total			NB	No Benefit
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Υ		NQ	Not Required
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)			NQ	Not Required
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)			NQ	Not Required
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Υ		NQ	Not Required
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Υ			
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		16.13%	R	Reportable
12-17 Years		25.71%	R	Reportable

Total		20.90%	R	Reportable
Effectiveness of Care: Medication				
Annual Monitoring for Patients on Persistent	Υ			
Medications (mpm)	Ĭ			
ACE Inhibitors or ARBs			NQ	Not Required
Diuretics			NQ	Not Required
Total			NQ	Not Required
Effectiveness of Care:				
Non-Recommended Cervical Cancer Screening in				
Adolescent		0.18%	R	Reportable
Females (ncs)				
Appropriate Treatment for Children With URI (uri)	Υ	91.48%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Υ		NQ	Not Required
Use of Imaging Studies for Low Back Pain (Ibp)			NQ	Not Required
Use of Multiple Concurrent Antipsychotics in Children				
and	Υ			
Adolescents (apc)				
1-5 Years		0.00%	NA	Small Denominator
6-11 Years		0.00%	NA	Small Denominator
12-17 Years		0.00%	NA	Small Denominator
Total		0.00%	R	Reportable
Use of Opioids at High Dosage (uod)	Υ		NA	Small Denominator
Use of Opioids From Multiple Providers (uop)	Υ			
Multiple Prescribers			NA	Small Denominator
Multiple Pharmacies			NA	Small Denominator
Multiple Prescribers and Multiple Pharmacies			NA	Small Denominator
Access/Availability of Care				
Adults' Access to Preventive/Ambulatory Health				
Services (aap)				
20-44 Years			NQ	Not Required
45-64 Years			NQ	Not Required
65+ Years			NQ	Not Required
Total			NQ	Not Required
Children and Adolescents' Access to Primary Care				
Practitioners (cap)				

12-24 Months		99.16%	R	Reportable
25 Months - 6 Years		93.84%	R	Reportable
7-11 Years		96.02%	R	Reportable
12-19 Years		95.26%	R	Reportable
Annual Dental Visit (adv)	N	93.2070	IX.	reportable
2-3 Years	14		NB	No Benefit
4-6 Years			NB	No Benefit
7-10 Years			NB	No Benefit
11-14 Years			NB	No Benefit
15-18 Years			NB	No Benefit
19-20 Years			NB NB	No Benefit
Total			NB NB	No Benefit
			IND	140 Bellelit
Initiation and Engagement of AOD Abuse or Dependence Treatment (iet)	N			
Alcohol abuse or dependence: Initiation of AOD Treatment: 13-17 Years			NB	No Benefit
Alcohol abuse or dependence: Engagement of AOD Treatment: 13-17 Years			NB	No Benefit
Opioid abuse or dependence: Initiation of AOD Treatment: 13-17 Years			NB	No Benefit
Opioid abuse or dependence: Engagement of AOD Treatment: 13-17 Years			NB	No Benefit
Other drug abuse or dependence: Initiation of AOD Treatment: 13-17 Years			NB	No Benefit
Other drug abuse or dependence: Engagement of AOD Treatment: 13-17 Years			NB	No Benefit
Total: Initiation of AOD Treatment: 13-17 Years			NB	No Benefit
Total: Engagement of AOD Treatment: 13-17 Years			NB	No Benefit
Alcohol abuse or dependence: Initiation of AOD Treatment: 18+ Years			NB	No Benefit
Alcohol abuse or dependence: Engagement of AOD Treatment: 18+ Years			NB	No Benefit
Opioid abuse or dependence: Initiation of AOD Treatment: 18+ Years			NB	No Benefit
Opioid abuse or dependence: Engagement of AOD Treatment: 18+ Years			NB	No Benefit

·				
Other drug abuse or dependence: Initiation of AOD Treatment: 18+ Years			NB	No Benefit
Other drug abuse or dependence: Engagement of AOD			ND	N. D. 6
Treatment: 18+ Years			NB	No Benefit
Total: Initiation of AOD Treatment: 18+ Years			NB	No Benefit
Total: Engagement of AOD Treatment: 18+ Years			NB	No Benefit
Alcohol abuse or dependence: Initiation of AOD Treatment:  Total			NB	No Benefit
Alcohol abuse or dependence: Engagement of AOD Treatment: Total			NB	No Benefit
Opioid abuse or dependence: Initiation of AOD Treatment: Total			NB	No Benefit
Opioid abuse or dependence: Engagement of AOD Treatment: Total			NB	No Benefit
Other drug abuse or dependence: Initiation of AOD Treatment: Total			NB	No Benefit
Other drug abuse or dependence: Engagement of AOD Treatment: Total			NB	No Benefit
Total: Initiation of AOD Treatment: Total			NB	No Benefit
Total: Engagement of AOD Treatment: Total			NB	No Benefit
Prenatal and Postpartum Care (ppc)				
Timeliness of Prenatal Care			NQ	Not Required
Postpartum Care			NQ	Not Required
Use of First-Line Psychosocial Care for Children and	N			
Adolescents on Antipsychotics (app	IN .			
1-5 Years			NB	No Benefit
6-11 Years			NB	No Benefit
12-17 Years			NB	No Benefit
Total			NB	No Benefit
Utilization				
Well-Child Visits in the First 15 Months of Life (w15)				
0 Visits		0.26%	R	Reportable
1 Visit		0.51%	R	Reportable
2 Visits		1.29%	R	Reportable
3 Visits		2.83%	R	Reportable
4 Visits		3.60%	R	Reportable
5 Visits		15.17%	R	Reportable

6+ Visits		76.35%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth		84.91%	R	Reportable
Years of Life (w34)				'
Adolescent Well-Care Visits (awc)		71.78%	R	Reportable
Frequency of Selected Procedures (fsp)			R	Reportable
Ambulatory Care: Total (amba)			NQ	Not Required
Ambulatory Care: Dual Eligibles (ambb)			NQ	Not Required
Ambulatory Care: Disabled (ambc)			NQ	Not Required
Ambulatory Care: Other (ambd)			NQ	Not Required
Inpatient UtilizationGeneral Hospital/Acute Care: Total (ipua)			R	Reportable
Inpatient UtilizationGeneral Hospital/Acute Care: Dual Eligibles (ipub)			NQ	Not Required
Inpatient UtilizationGeneral Hospital/Acute Care: Disabled (ipuc)			NQ	Not Required
Inpatient UtilizationGeneral Hospital/Acute Care: Other (ipud)			NQ	Not Required
Identification of Alcohol and Other Drug Services:  Total (iada)	N		NB	No Benefit
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N		NB	No Benefit
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N		NB	No Benefit
Identification of Alcohol and Other Drug Services: Other (iadd)	N		NB	No Benefit
Mental Health Utilization: Total (mpta)	N		NB	No Benefit
Mental Health Utilization: Dual Eligibles (mptb)	N		NB	No Benefit
Mental Health Utilization: Disabled (mptc)	N		NB	No Benefit
Mental Health Utilization: Other (mptd)	N		NB	No Benefit
Antibiotic Utilization: Total (abxa)	Υ		R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	Υ		NQ	Not Required
Antibiotic Utilization: Disabled (abxc)	Υ		NQ	Not Required
Antibiotic Utilization: Other (abxd)	Υ		NQ	Not Required
Standardized Healthcare-Associated Infection Ratio (hai)			NQ	Not Required

Risk Adjusted Utilization		
Plan All-Cause Readmissions (pcr)	NQ	Not Required
Health Plan Descriptive		
Board Certification (bcr)	NQ	Not Required
Enrollment by Product Line: Total (enpa)	R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	NQ	Not Required
Enrollment by Product Line: Disabled (enpc)	NQ	Not Required
Enrollment by Product Line: Other (enpd)	NQ	Not Required
Enrollment by State (ebs)	R	Reportable
Language Diversity of Membership (Idm)	R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	R	Reportable
Total Membership (tlm)	R	Reportable
Measures Collected using Electronic		
Depression Screening and Follow-Up for Adolescents		
and Adults (dsf)		
Depression Screening: Total Total	NR	Not Reported
Follow-up on Positive Screen: Total Total	NR	Not Reported
Utilization of the PHQ-9 to Monitor Depression		
Symptoms		
for Adolescents and Adults (dms)		
Utilization of PHQ-9: Total Total	NR	Not Reported
Depression and Remission or Response for Adolescents		
and Adults (drr)		
Follow-up PHQ-9: Total Total	NR	Not Reported
Depression Remission: Total Total	NR	Not Reported
Depression Response: Total Total	NR	Not Reported
Unhealthy Alcohol Use Screening and Follow-Up (asf)		
Alcohol Use Screening: Total Total	NR	Not Reported
Counseling or Other Follow-up Postive Screen: Total Total	NR	Not Reported